Lilly's $30.6M tax abatement request clears hurdle

Back to TopCommentsE-mailPrintBookmark and Share

Eli  Lilly and Co.’s request for more than $30 million in tax breaks on $400 million in construction projects and improvements to existing operations downtown has cleared a hurdle with the city’s Metropolitan Development Commission.

The Commission granted preliminary approval Wednesday afternoon on Lilly's two 10-year tax abatement requests totaling $30.6 million. A public hearing and final consideration are now scheduled for May 1.

Over the last several months, the pharmaceuticals giant has rolled out plans for a manufacturing plant southwest of downtown Indianapolis where the firm will manufacture cartridges for insulin.  

Construction is already under way for the 164,000-square-foot plant on South Harding Street, adjoining Lilly’s existing manufacturing complex known as Lilly Technology Center.

Lilly’s investment in the project is estimated at $320 million. In addition, it is planning a new inspection facility that will add another 30,000 square feet to the project, plus renovations to existing buildings on the Lilly Technology Center campus and to the Lilly Corporate Center. In total, Lilly’s investment is expected to reach $400 million.

MDC staff opined in a report to the commission that the project would not be economically feasible without the tax abatement.

The staff report states that the new investments will allow Lilly to retain 175 local employees, who will earn an average of $30.94 an hour. A company spokesman has said that the project would involve a combination of existing employees and new workers.

Over the 10-year abatement period, Lilly still would pay $25.4 million in taxes. After that, it would pay about $5.2 million in taxes annually related to the projects.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
thisissue1-092914.jpg 092914

Subscribe to IBJ